Home » Ranbaxy Signs FDA Consent Decree, Diverts $500 Million for Fraud Probe
Ranbaxy Signs FDA Consent Decree, Diverts $500 Million for Fraud Probe
Indian generic-drug giant Ranbaxy Laboratories entered into a consent decree with the FDA to resolve lingering manufacturing problems at two plants.
Generic Line
Generic Line
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May